Company: CMND
Filing Date: 2025-11-19
Form Type: 6-K
Source: 0001213900-25-112331
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-19
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: November 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form 40-F ☐

CONTENTS</div>

On November 19, 2025, Clearmind Medicine (the “Company”),
entered into a securities purchase agreement (the “Securities Purchase Agreement”) with investors for the purchase and sale
of 10,925,000 of the Company’s common shares, no par value (the “Common Shares”), in a registered direct offering (the
“Offering”) at a purchase price of $0.20 per Common Share.

The Offering is expected to close on or about November 20, 2025, subject
to the satisfaction of customary closing conditions. The aggregate gross proceeds to the Company are expected to be approximately $2.185
million. The Company expects to use the net proceeds from the Offering, together with its existing cash, for general corporate purposes,
which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates,
working capital, future acquisitions and general capital expenditures.

The Securities Purchase Agreement
also contains representations, warranties, indemnification and other provisions customary for transactions of this nature.

The securities described above and to be issued in the Offering are
being issued pursuant to a prospectus supplement dated as of November 19, 2025, which will be filed with the Securities and Exchange Commission,
in connection with a takedown from the Company’s shelf registration statement on Form F-3 (File No. 333-275991) (the “Registration
Statement”), which became effective on December 26, 2023, and the base prospectus dated as of December 26, 2023 contained in such
Registration Statement. This Report on Form 6